U.S. markets closed

Mirati Therapeutics, Inc. (MRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
41.99-1.57 (-3.60%)
At close: 04:00PM EDT
42.83 +0.84 (+2.00%)
After hours: 07:33PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close43.56
Bid40.35 x 1800
Ask43.12 x 800
Day's Range41.54 - 43.70
52 Week Range27.30 - 101.30
Avg. Volume1,334,691
Market Cap2.935B
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-13.55
Earnings DateNov 06, 2023 - Nov 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.24
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MRTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Mirati Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • PR Newswire

    Mirati To Present Updated Clinical Data at ESMO Congress 2023

    Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development biotechnology company, today announced several presentations to be unveiled at the European Society of Medical Oncology Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data showcasing the feasibility and potential of the investigational combination of KRASG12C inhibitor, adagrasib with pembrolizumab in a study of treatment naïve patients with advanced non-small ce

  • PR Newswire

    Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer

    Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib (KRAZATI®) in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

  • PR Newswire

    Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).